1446250-90-3Relevant articles and documents
Discovery of TD-8954, a clinical stage 5-HT4 receptor agonist with gastrointestinal prokinetic properties
McKinnell, R. Murray,Armstrong, Scott R.,Beattie, David T.,Fatheree, Paul R.,Long, Daniel D.,Marquess, Daniel G.,Shaw, Jeng-Pyng,Vickery, Ross G.
, p. 4210 - 4215 (2013)
The discovery of a series of 5-HT4 receptor agonists based on a novel 2-alkylbenzimidazole aromatic core is described. Optimization of the 2-substituent of the benzimidazole ring led to a series of agonists with subnanomolar binding affinity and moderate-to-high intrinsic activity relative to that of 5-HT. Consistent with our previously described multivalent design approach to this target, subsequent optimization of the linker and secondary binding group regions of the series afforded compound 18 (TD-8954), a potent and selective 5-HT4 receptor agonist in vitro with demonstrated prokinetic activity in multiple species.